Key changes between ICH GCP E6 R3 and E6 R2. Critical updates between ICH GCP E6 R2 and R3 that every clinical research professional needs to know

Updated on June 6th, 2026.

On January 6, 2025, the International Council for Harmonisation (ICH) made changes to the Good Clinical Practice (GCP) guidelines. They adopted the updated ICH E6 R3 guideline. This change marks an important step in improving the standards for ethical and scientific clinical trials. This new version addresses the technological advancements and the complexities associated with modern clinical research.

Key quality concepts in ICH E6 R3 now include trial conduct and design. These factors are important for study quality and risk management. The new ICH E6 R3 guideline affects every step of the trial conduct process, including preparation, execution, documentation, supervision, assessment, analysis, and reporting.

Here’s a clear overview of the main updates from E6 R2 to E6 R3. This includes important effects for different stakeholders. If you’ve been asked which of the following statements appears in ICH E6 R3, whether in a GCP certification exam or a compliance training assessment, this article quotes the exact language from the guideline so you can identify the correct answers with confidence. If you’ve been asking yourself which of the following is an ICH E6 R3 requirement, whether in preparation for a GCP certification exam or ahead of a regulatory inspection, the breakdown below covers every major update in plain, practical terms.

What is ICH GCP, and are ICH and GCP the same thing?

If you are new to clinical research, you may wonder whether ICH and GCP refer to the same thing. The short answer is no, but they are closely related.
ICH stands for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It is the international body that brings together regulatory authorities from the US, Europe, Japan, and other regions, along with industry representatives, to develop harmonized guidelines for drug development. ICH produces a wide range of guidelines across areas such as safety, quality, efficacy, and multidisciplinary topics.
GCP, or Good Clinical Practice, is one specific ICH guideline, identified as “E6”, that sets the international standard for the design, conduct, oversight, and reporting of clinical trials. Its main purpose is to protect the rights, safety, and well-being of trial participants and to ensure the reliability of trial data.
So when people say “ICH GCP,” they are referring to ICH’s E6 guideline on Good Clinical Practice. The full name is ICH E6, and it has gone through several revisions: the original version (1996), E6 R1 (1996/2002), E6 R2 (2016), and now E6 R3 (2025). The difference between ICH GCP E6 R2 and R3 is the focus of this article.

What is GCP R2?

ICH GCP E6 R2, commonly referred to as GCP R2, is the second major revision of the Good Clinical Practice guideline, adopted by ICH in 2016 and in effect until June 2025. It introduced important updates compared to the original 1996 version, particularly around sponsor oversight, electronic records and signatures, risk-based monitoring, and audit trail requirements.
R2 was a significant step forward at the time, but it was developed in an era before decentralized clinical trials, electronic consent, real-world data, and advanced digital health technologies became widespread. Those limitations are exactly what prompted ICH to develop E6 R3, which came into force in 2025 and is now the current standard, as explained in detail in the sections below.

Significant ICH E6 R3 changes

The updated ICH E6 R3 version introduces substantial changes to both the structure and content of the GCP guidelines.

The updated structure is:

• Introduction
• Principles
• Annex 1:
  1. Institutional review board/independent ethics committee (IRB/IEC)
  2. Investigator
  3. Sponsor
  4. Data governance – Investigator and sponsor.
• Glossary
• Appendices:
  1. Investigator’s Brochure
  2. Clinical trial protocol and protocol amendment 
  3. Essential records for conducting a clinical trial.
• Annex 2:
  1. Institutional review board/independent ethics committee (IRB/IEC)
  2. Investigator
  3. Sponsor

The major changes made to the content are focused on:

• Guiding guidelines
• Primacy of principles
• Focus on technology
• Quest for Quality
• Elaboration of ethics
• Rising responsibilities.

ICH E6 R3 Glossary

This section contains both new additions and changes to the E6 R2 definitions. For anyone studying which of the following statements appears in ICH E6 R3, the definitions below are quoted verbatim from the official guideline, making it easy to recognise exact wording in exam questions.:

• The definition of GCP has been updated:

  • In GCP E6 R2, GCP is “a standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial subjects are protected”.
  • In the GCP E6 R3, the GCP definition changes the description of clinical trial processes and aspects that must be assured and states: “GCP is a standard for the planning, initiating, performing, recording, oversight, evaluation, analysis, and reporting of clinical trials that provides assurance that the data and reported results are reliable and that the rights, safety, and well-being of trial participants are protected”.
• In ICH E6 R3, the term “Trial participant” replaces “subject”.

• The R3 defines a “Clinical trial as “Any interventional investigation in human participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s); and/or to identify any adverse reactions to an investigational product(s); and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy”

• The term “Source records” has replaced “source documents and data”, and refers to “original documents or data (which include relevant metadata) or certified copies of the original documents or data, irrespective of the media used. This may include trial participants’ medical/health records/notes/charts; data provided/entered by trial participants (e.g., electronic patient-reported outcomes [ePROs]); health-care providers’ records from pharmacies, laboratories, and other facilities involved in the clinical trial; and data from automated instruments, such as wearables and sensors”.

The glossary now includes new terms such as:

• assent,
• audit trail,
• data acquisition tool,
• metadata,
• Reference Safety Information,
• signature,
• Suspected Unexpected Serious Adverse Reactions (SUSAR).

Guiding Guidelines

The ICH recommends reading the ICH GCP E6 R3 guidelines, as well as other ICH guidelines. These guidelines cover clinical trial design and conduct, including multiregional trials. This new guideline references other ICH guidelines in the following areas:

• Introduction:  E8 R1 General Considerations for Clinical Studies
• Clinical trial/study reports: E3 Structure and Content of Clinical Study Reports
• Safety reporting: (1) E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (2) E19 on a selective approach to safety data collection in specific late-stage preapproval or postapproval clinical trials
• Reference Safety Information: E2F Development Safety Update Report
• Statistical programming and data analysis: E9 Statistical Principles for Clinical Trials
• Data governance, Investigator and sponsor: E8 R1, E9
• Serious adverse event: E2A
• Clinical Trial Protocol and Protocol Amendment(s): E8 R1, E9, E9 R1 addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials.

ICH E6 R3 fundamental principles

A question that comes up frequently, both in certification exams and in real-world compliance reviews, is: which of the following is an ICH E6 R3 requirement that didn’t exist in R2? The principles section is where many of the most significant new requirements live. The principles are important in the ICH GCP E6 R3 guidelines. They apply to many types of clinical trials. They also stay relevant as methods and technology improve. To help with trial design and conduct, Annex 1 shows how key stakeholders can use these flexible principles. These stakeholders include the IRB/IEC, investigator/institution, and sponsor.

The ICH GCP E6 R2 principles are part of the ICH GCP E6 R3 principles. These are intended to protect participants’ rights, safety, and well-being. A common exam question asks which of the following statements appears in ICH E6 R3 regarding principles, the answer is always rooted in the risk management, scientific quality, and reliability of results language introduced in R3. They also cover informed consent, IRB/IEC approval, and having qualified people conduct the protocol. Additionally, they address investigational product management.

The new ICH GCP E6 R3 principles focus on risk management, strong science, and quality. They also emphasize the reliability of results, as well as the roles and responsibilities of sponsors and investigators.

Each principle is explained in this guideline along with examples of how to apply them. The principles are interrelated and should be considered in their totality to ensure ethical trial conduct and reliable results.

Difference between ICH E6 R2 and ICH E6 R3

1. Enhanced Data Integrity and Lifecycle Management
   • E6 R2 Challenges: The previous guideline had a limited focus on data security and lifecycle management, leading to gaps in how sponsors ensured the security and integrity of critical data.
   • E6 R3 Enhancements: The updated guideline provides a robust framework, requiring sponsors to secure data across all phases—from collection, storage, and access, to disposal. This ensures that data remains unaltered and prevents unauthorized access, aligning clinical research practices with current digital standards.
2. Quality by Design and Risk Management
   • E6 R2 Approach: Risk management was more retrospective, often addressing issues as they arose.
   • E6 R3 Approach: There’s a stronger focus on proactively identifying and managing risks critical to participant safety and data reliability. The principle of Quality by Design (QbD) is integrated into every stage of the trial process, emphasizing the importance of designing trials to mitigate risks effectively. ICH E6 R3 seeks to cultivate a quality-focused culture by embedding quality considerations into clinical trials and drug development plans from the outset. This guideline advocates for the implementation of QbD to pinpoint the crucial data and processes necessary for maintaining trial quality, identify risks that could undermine these elements, and ensure the reliability of trial outcomes. Throughout the guideline, there is a consistent emphasis on ensuring quality. Key clinical trial activities such as monitoring and data management, are highlighted as essential quality control measures. The integration of new technologies has set higher standards for quality and increased the responsibilities of stakeholders.
3. Modernized Data Governance
   • E6 R2 Limitations: Data governance guidelines were less comprehensive, often leading to inconsistencies in data handling practices.
   • E6 R3 Innovations: The updated guideline dedicates a section to data integrity and traceability throughout the entire data lifecycle. This modernization ensures better regulatory compliance and credibility of trial outcomes.
4. Flexibility for Diverse Trial Designs and Technological Advances
   • E6 R2 Flexibility: Limited provisions for innovative trial designs and modern technologies.
   • E6 R3 Flexibility: Recognizes and encourages the use of adaptive, platform, and decentralized trial designs. It supports electronic informed consent, remote monitoring, and other technological innovations, making trials more adaptable and efficient.
5. Clearly Defined Roles and Responsibilities
   • E6 R2 Structure: Roles and responsibilities were outlined, but lacked detailed guidance on certain aspects.
   • E6 R3 Clarity: Provides enhanced and detailed descriptions of sponsors, investigators, and service providers’ roles. This clarity facilitates better coordination and oversight throughout the trial process.
6. Reinforced Ethical and Participant Protections
   • E6 R2 Focus: Ethical guidelines were present but needed reinforcement in the context of evolving trial designs and technologies.
   • E6 R3 Reinforcement: Strengthens obligations of independent review boards (IRBs) and ethics committees (IECs), ensuring independence, thorough protocol review, and continuous safety oversight to safeguard participant rights and welfare. This new version includes both the ethical considerations outlined in E6 R2, which have long been the backbone of GCP, and current ethical issues stemming from new technological approaches to trial design and implementation. Its emphasis is on protecting participant rights under varied conditions, such as emergency research and electronic consent, ensuring transparency in clinical trials and results sharing, and maintaining privacy and confidentiality. By integrating ethical obligations into the guiding principles, the guidelines aim to help clinical research professionals uphold high ethical standards when confronted with new challenges. However, this expansion of ethical requirements is expected to increase the workload of ethical review boards.
7. Thrust of Technology
   • E6 R2 Focus: E6 R2 was updated to promote the adoption of technological advancements aimed at improving the efficiency of clinical trial conduct.
   • E6 R3 Enhancement: E6 R3 further refines the guidelines to incorporate cutting-edge technologies in clinical trial management. The guideline remains media-neutral, allowing for the use of various technologies for documentation purposes. It advises that technology use in clinical trials should be adapted to match participant characteristics and the specific trial design. This emphasis on technology pervades all aspects of trial conduct, quality, ethics, and stakeholder responsibilities, driving forward the modernization of clinical research practices.

Detailed implications and preparatory steps for stakeholders

Sponsors

1. Comprehensive Data Management: Sponsors must implement strong data integrity measures across all trial phases. This means ensuring data reliability and preventing unauthorized access from collection to disposal.
   1. Preparation: Develop and integrate robust data management systems that comply with new standards. Train staff on data security practices to ensure compliance across the board.
   2. Benefit: Enhanced credibility of trial data, leading to increased trust from regulatory bodies and participants.
2. Proactive Risk Management: Emphasizing quality by design means sponsors must proactively identify and manage risks throughout the trial lifecycle.
   1. Preparation: Early-stage integration of risk management strategies to design trials that anticipate and mitigate potential issues.
   2. Benefit: Improved trial efficiency and participant safety, reducing the likelihood of costly and time-consuming issues.
3. Technological Adaptation: ICH E6 R3 encourages adopting innovations like electronic informed consent and remote monitoring.
   1. Preparation: Invest in modern technologies and train staff in their use. Develop protocols that incorporate these tools seamlessly into trial processes.
   2. Benefit: Streamlined trial processes, enhanced participant engagement, and better data quality.

Contract Research Organizations (CROs)

1. 1. Compliance and Innovation: CROs must ensure adherence to the new guidelines while integrating innovative trial technologies.
      1. • Preparation: Update standard operating procedures (SOPs) to reflect new requirements. Foster a culture of innovation and compliance within the organization.
      2. • Benefit: Competitive edge and enhanced service offerings to sponsors.
   2. Streamlined Data Governance: Implementing data integrity measures to ensure traceability and reliability.
      1. • Preparation: Develop comprehensive data governance frameworks and conduct regular audits to ensure compliance.
      2. • Benefit: Improved data quality and regulatory compliance, leading to smoother approval processes.
   3. Enhanced Training and Oversight: Ensuring that staff are well-trained and maintaining oversight over delegated tasks.
      1. • Preparation: Implement thorough training programs and establish clear oversight mechanisms. • Benefit: Higher quality of trial execution and better compliance with trial protocols.

Trial Sites

1. 1. Increased Oversight: Trial sites need to adhere to the enhanced requirements for oversight and accountability.
      1. • Preparation: Establish clear procedures for monitoring and documenting trial activities. Ensure staff are trained in the latest guidelines.
      2. • Benefit: Higher standard of trial conduct and improved data integrity.
   2. Data Integrity Focus: Sites must comply with the stringent data handling practices required by E6(R3).
      1. • Preparation: Implement systems that ensure data is accurately captured, stored, and maintained. Regularly train staff on data handling protocols.
      2. • Benefit: Enhanced accuracy and reliability of trial data.
   3. Ethical Considerations: Maintaining high ethical standards, especially in informed consent and participant communication.
      1. • Preparation: Ensure informed consent processes are clear and accessible for all participants, incorporating technology where appropriate.
      2. • Benefit: Enhanced participant trust and adherence to ethical standards.

Trial Participants

1. 1. Better Protection: Participants are better protected with enhanced data security and lifecycle management.
      1. • Benefit: Greater transparency and trust in the clinical trial process.
   2. Improved Consent Processes: Electronic informed consent ensures participants are well-informed and their autonomy is respected.
   3. • Benefit: Participants are more engaged and informed, leading to higher retention rates and better overall trial participation.

Embrace the future: Key steps for stakeholders

Whether you’re a sponsor, CRO, or site professional wondering which of the following is an ICH E6 R3 requirement you need to act on immediately, the answer starts with a thorough review of the updated guideline. Good Clinical Practice guidelines have long been the cornerstone of ethical and scientifically rigorous clinical trials. Whether you’re preparing for a GCP certification and trying to identify which of the following statements appears in ICH E6 R3, or leading an implementation team preparing for inspections, the steps below apply equally. With the final approval of ICH E6 R3, all stakeholders need to become well-acquainted with the significant updates and prepare for their implementation. This constitutes STEP 4: ICH has officially adopted the final version. However, the process carries forward to STEP 5: the practical application of these guidelines.

Immediate action required: Understand and adapt to ICH E6 R3

Key stakeholders should thoroughly review the newly adopted guideline to comprehend the major changes. Even before the guidelines are fully enforced, now is the best time to start planning and implementing changes. While you wait for the transition, remember that ICH GCP E6 R2 remains in effect. Ensure that your team receives regular Good Clinical Practice training. They should also hold a valid Good Clinical Practice certification. It is critical that your Good Clinical Practice training is up to date. You should update it every three years. This helps to ensure that clinical research adheres to high standards.

When was ICH GCP R3 implemented?

The ICH E6 R3 Guideline for Good Clinical Practice has now been implemented or formally adopted by major regulatory authorities worldwide. Implementation timelines differ by region, and the difference between ICH GCP E6 R2 and R3 obligations therefore depends on where your clinical trial is being conducted.
Here is the current status by country and region:

• EU / EMA: The European Medicines Agency (EMA) released ICH E6 R3 Step 5 on January 27, 2025. E6 R2 remained in effect until June 11, 2025. E6 R3 Principles and Annex 1 became effective from June 12, 2025, and entered legal effect in the EU on July 23, 2025. Clinical trials conducted in the EU must now comply with E6 R3.
• United States / FDA: On September 8, 2025, the U.S. Food and Drug Administration (FDA) issued its final guidance for industry on ICH E6(R3) Good Clinical Practice and published it in the Federal Register. This makes the guideline officially available in the United States. However, it is important to note that FDA guidance documents are not legally binding in the same way as EU regulations, they reflect the agency’s current thinking and expectations. The FDA has not yet announced a formal compliance date for US trials. That said, early adoption is strongly encouraged, as FDA-regulated trials are expected to align with E6 R3 principles. See the dedicated FAQ below for a detailed answer to “Is ICH E6 R3 mandatory in the US?”
• Switzerland / Swissmedic: Adopted E6 R3 in August 2025, shortly after the EU.
• United Kingdom / MHRA: The Medicines and Healthcare products Regulatory Agency (MHRA) published UK-specific annotations to ICH E6 R3 on January 12, 2026, adapting the guideline for the UK regulatory framework.
• Japan / PMDA: Japan is expected to follow ICH’s adoption timeline. Organizations conducting trials in Japan should monitor PMDA announcements for confirmation of their specific implementation date.
• Other ICH member countries: Canada, Australia, and other ICH member countries are expected to adopt E6 R3 in accordance with their own regulatory processes and timelines. Organizations should check with local regulatory authorities for specific effective dates.

Regarding ICH E6 R3 Annex 2:

Annex 2 covers additional considerations for non-traditional trials, including decentralized, platform, and registry-based designs. The ICH Assembly formally adopted ICH E6(R3) Annex 2 on June 3rd, 2026, bringing it to Step 4. This is a significant milestone, establishing the finalised, definitive global standard for non-traditional interventional clinical trials.

ICH E6 R3 Next Steps

• Review the final guideline document available on the ICH website.
• Plan for training and implementation within your organization or take our New ICH GCP E6 R3 course.
• Stay tuned for further guidance and resources from regulatory bodies.

In order to promote more effective, moral, and significant clinical trials, let us welcome these updates.

Obtain your Good Clinical Practice Certification on the ICH E6 R3 guideline now!

PharmaEduCenter recognizes the importance of high-quality, efficient online training for research professionals with demanding schedules. PharmaEduCenter understands research professionals’ busy schedules and the value of high-quality, efficient online training. We are pleased to announce the release of our new Good Clinical Practice training on the new ICH GCP E6 R3 guideline. It contains important updates to the ICH E6 R3 guidelines. Join the thousands of people who have already benefited from our thorough, practical, and convenient online training. Earn your GCP certification at your own pace with ease and confidence. Click here to sign up now!

The future of clinical research is here

The arrival of ICH E6 R3 marks an important change in clinical research. It focuses on more ethical, safer, and efficient practices. By adopting this transformative framework, we can lead the way in achieving better healthcare solutions and improved patient outcomes. The new guidelines aim to start a new era of clinical trials. These trials will focus on participant safety, ethical standards, and strong scientific integrity.

As we move forward, it’s essential to embrace these changes, ensuring all stakeholders are well-prepared for the advancements brought by ICH E6 R3. A proactive approach will undoubtedly contribute to our shared goal of advancing clinical research and delivering superior healthcare solutions.

Key takeaways

Understanding the difference between ICH GCP E6 R2 and R3 is essential for every clinical research professional operating today. Here is a concise summary of what you need to remember:

• ICH E6 R3 is now in effect in the EU (since July 23, 2025), the US (FDA final guidance September 8, 2025), Switzerland (August 2025), and the UK (MHRA annotations January 12, 2026).
• E6 R2 has been superseded as the reference standard for ICH GCP compliance. Good Clinical Practice training and certification should be updated to the E6 R3 version.
• 7 essential changes distinguish E6 R3 from R2: enhanced data integrity, Quality by Design, modernized data governance, flexibility for diverse trial designs, clearly defined roles, reinforced ethical protections, and strengthened technology integration.
• Quality by Design (QbD) is central to E6 R3. Sponsors must now embed quality management into trial planning from the outset, not address issues reactively.
• Technology neutrality is a guiding principle: E6 R3 accommodates electronic consent, remote monitoring, decentralized trials, and digital health tools without mandating specific platforms.
• Terminology has changed: “trial participant” replaces “subject,” and “source records” replaces “source documents and data.”
• Annex 2, covering non-traditional trial designs, was finally adopted on June 3rd, 2026. Organizations running decentralized or platform trials should monitor their development closely.
• Good Clinical Practice training must be updated at least every three years. If your GCP certification is based on E6 R2, it is time to renew with an ICH GCP course aligned with E6 R3.

If you are setting up a clinical trial site or training as a principal investigator, you can also explore our course on how to set up a clinical trial site and the fundamentals of clinical trials for a complete foundation in clinical research compliance.